SEAMARK: Phase II Study of First-Line Encorafenib and Cetuximab Plus Pembrolizumab for MSI-H/dMMR BRAFV600E-mutant Mcrc.
FUTURE ONCOLOGY（2024）
Key words
BRAF V600,cetuximab,dMMR,encorafenib,immunotherapy,metastatic colorectal cancer,MSI-H,pembrolizumab,targeted therapy,triplet combination therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined